Drug Database · Clinicians

Phentermine

Brands (2) Duromine 15, Duromine 30Show all

US brand (reference label): LOMAIRA; not a Philippine-registered brand.

Anti-obesity PH FDA category

S2 · Dangerous drug — PDEA S2 license required; see prescription rules belowRx · Prescription drug2 PH products

1971 Convention Schedule IV; Philippine Schedule 4; PDEA S-2 license required. Oral FDA-registered Philippine Schedule 4 preparations: ordinary prescription in triplicate (BR 1 s.2014 Sec. 4(4)(a)); other forms: DOH Special Prescription Form (yellow) (Sec. 31(2)). No refill; up to a 30-day supply, 60 days for epilepsy and dystonia (Sec. 31(6)(d)-(e)). Until June 30, 2027, S-2 licensed practitioners may use an ordinary prescription in triplicate instead of the special form (one dangerous drug per prescription, "NO REFILL", up to 30 days; 60 days for Philippine Schedule 4 drugs in epilepsy and dystonia) (BR 10 s.2025, extended by BR 5 s.2026). Source: DDB, Updated Lists of Scheduled Controlled Substances (as of 20 July 2026); Republic Act No. 9165, Comprehensive Dangerous Drugs Act of 2002; DDB Board Regulation No. 3, s. 2020 (CBD drug products; defines Philippine Schedules 1-4); DDB Board Regulation No. 1, s. 2014 (amending BR 3 s. 2003: licensing, prescriptions, exemptions); DDB Board Regulation No. 10, s. 2025 (temporary authorization of ordinary prescriptions for dangerous drugs); DDB Board Regulation No. 5, s. 2026 (ordinary prescriptions for dangerous drugs extended to June 30, 2027).

Dispensing: Prescription (Rx) · Dangerous drug (S2) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 0718f0f3-77f2-45d7-be12-1ed718c8b806, version date May 21, 2026 (LOMAIRA · Calvin Scott & Co., Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE LOMAIRA™ tablets are indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of…
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE LOMAIRA™ tablets are indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity in patients with an initial body mass index greater than or equal to 30 kg/m 2, or greater than or equal to 27 kg/m 2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). Below is a chart of body mass index (BMI) based on various heights and weights.

BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters. BODY MASS INDEX (BMI), kg/m 2 The limited usefulness of agents of this class, including phentermine (see Clinical Pharmacology), should be measured against possible risk factors inherent in their use such as those described below. table

Contraindications

CONTRAINDICATIONS • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy (see Precautions) • Nursing (see Precautions) • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Dosage should be individualized to obtain an adequate response with the lowest effective dose. The usual adult dose is one tablet three times a day ½ hour before meals. This tablet is scored to facilitate administering one half of the usual dosage for patients not requiring the full dose. Phentermine hydrochloride is not recommended for use in pediatric patients less than or equal to 16 years of age. Late evening medication should be avoided because of the possibility of resulting insomnia.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (pharmacokinetics)

Renal Impairment Phentermine was not studied in patients with renal impairment. The literature reported cumulative urinary excretion of phentermine under uncontrolled urinary pH conditions is 62%-85%. Exposure increases can be expected in patients with renal impairment. Use caution when administering phentermine to patients with renal impairment.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Capsule: 15 mg, 30 mg

Registered products in the Philippines

2 products registered with the Food and Drug Administration (FDA) Philippines list Phentermine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Phentermine
Package insert
Duromine 15Phentermine
15 mg CapsulePVC/PVDC Blister Pack x 15's (Box of 30's)
Rx
Douglas Manufacturing Ltd.New Zealand
iNova Pharma Philippines Inc.Trader: iNova Pharmaceuticals (S) Pte. Ltd.
DR-XY26998
Mar 26, 2031
Duromine 30Phentermine
30 mg CapsulePVC/PVDC Blister Pack x 15's (Box of 30's)
Rx
Douglas Manufacturing Ltd.New Zealand
iNova Pharma Philippines Inc.Trader: iNova Pharmaceuticals (S) Pte. Ltd
DR-XY26999
Mar 26, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS Coadministration with Other Drug Products for Weight Loss LOMAIRA™ tablets are indicated only as short-term (a few weeks) monotherapy for the management of exogenous obesity. The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established.

Therefore, coadministration of phentermine and these drug products is not recommended. Primary Pulmonary Hypertension Primary Pulmonary Hypertension (PPH) – a rare, frequently fatal disease of the lungs – has been reported to occur in patients receiving a combination of phentermine with fenfluramine or dexfenfluramine. The possibility of an association between PPH and the use of phentermine alone cannot be ruled out; there have been rare cases of PPH in patients who reportedly have taken phentermine alone.

The initial symptom of PPH is usually dyspnea. Other initial symptoms may include angina pectoris, syncope or lower extremity edema. Patients should be advised to report immediately any deterioration in exercise tolerance. Treatment should be discontinued in patients who develop new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema, and patients should be evaluated for the possible presence of pulmonary hypertension.

Valvular Heart Disease Serious regurgitant cardiac valvular disease, primarily affecting the mitral, aortic and/or tricuspid valves, has been reported in otherwise healthy persons who had taken a combination of phentermine with fenfluramine or dexfenfluramine for weight loss. The possible role of phentermine in the etiology of these valvulopathies has not been established and their course in individuals after the drugs are stopped is not known.

The possibility of an association between valvular heart disease and the use of phentermine alone cannot be ruled out; there have been rare cases of valvular heart disease in patients who reportedly have taken phentermine alone. Development of Tolerance, Discontinuation in Case of Tolerance When tolerance to the anorectant effect develops, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued.

Effect on the Ability to Engage in Potentially Hazardous Tasks Phentermine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly. Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and dll-amphetamine) and other related stimulant drugs have been extensively abused.

The possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. See Adverse Reactions / Drug Abuse and Dependence and Overdosage. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.

Usage with Alcohol Concomitant use of alcohol with phentermine may result in an adverse drug reaction. Use in Patients with Hypertension Use caution in prescribing phentermine for patients with even mild hypertension (risk of increase in blood pressure). Use in Patients on Insulin or Oral Hypoglycemic Medications for Diabetes Mellitus A reduction in insulin or oral hypoglycemic medications in patients with diabetes mellitus may be required.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS The following adverse reactions are described, or described in greater detail, in other sections: - Primary pulmonary hypertension (see Warnings) - Valvular heart disease (see Warnings) - Effect on the ability to engage in potentially hazardous tasks (see Warnings) - Withdrawal effects following prolonged high dosage administration (see Drug Abuse and Dependence) The following adverse reactions to phentermine have been identified: Cardiovascular Primary pulmonary hypertension and/or regurgitant cardiac valvular disease, palpitation, tachycardia, elevation of blood pressure, ischemic events. Central Nervous System Overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache, psychosis.

Gastrointestinal Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances. Allergic Urticaria. Endocrine Impotence, changes in libido.

Mechanism of action

Mechanism of Action Phentermine is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, amphetamine (d- and dll-amphetamine). Drugs of this class used in obesity are commonly known as “anorectics” or “anorexigenics.” It has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects, may also be involved.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

Pharmacodynamics Typical actions of amphetamines include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

The literature reported cumulative urinary excretion of phentermine under uncontrolled urinary pH conditions is 62%-85%.

Pharmacokinetics (US label) US FDA label

Pharmacokinetics Specific Populations Renal Impairment Phentermine was not studied in patients with renal impairment. The literature reported cumulative urinary excretion of phentermine under uncontrolled urinary pH conditions is 62%-85%. Exposure increases can be expected in patients with renal impairment. Use caution when administering phentermine to patients with renal impairment.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. LOMAIRA · Calvin Scott & Co., Inc. [US FDA-approved label, version 3, May 21, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0718f0f3-77f2-45d7-be12-1ed718c8b806
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .